H.C. Wainwright Maintains G1 Therapeutics(GTHX.US) With Buy Rating, Maintains Target Price $9

H.C. Wainwright analyst Edward White maintains $G1 Therapeutics(GTHX.US)$ with a buy rating, and maintains the target price at $9.According to TipRanks data, the analyst has a success rate of 32.7% an

moomoo News06:32 ET

Needham Maintains G1 Therapeutics(GTHX.US) With Buy Rating, Maintains Target Price $12

Needham analyst Gil Blum maintains $G1 Therapeutics(GTHX.US)$ with a buy rating, and maintains the target price at $12.According to TipRanks data, the analyst has a success rate of 40.7% and a total a

moomoo News02:32 ET

G1 Therapeutics Price Target Maintained With a $12.00/Share by Needham

G1 Therapeutics Price Target Maintained With a $12.00/Share by Needham

Dow Jones12:25 ET

G1 Therapeutics to Participate in TD Cowen's 5th Annual Oncology Innovation Summit

RESEARCH TRIANGLE PARK, N.C., May 22, 2024 (GLOBE NEWSWIRE) -- G1 Therapeutics, Inc. (NASDAQ:GTHX), a commercial-stage oncology company, today announced that G1's Chief Medical Officer Dr. Raj Malik and Chief

GlobeNewswireMay 22 10:00 ET

Express News | G1 Therapeutics Shares up 3.5% on Licensing Deal for Radioprotective Drug

ReutersMay 22 09:32 ET

Sector Update: Health Care Stocks Lower Premarket Wednesday

Health care stocks were lower premarket Wednesday as the iShares Biotechnology ETF (IBB) was 0.5% lower and the Health Care Select Sector SPDR Fund (XLV) was down 0.3% recently. Eupraxia Pharmaceutica

MT NewswiresMay 22 09:19 ET